Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia

Pharmacogenomics Journal

Volumn 12, Issue 3, 2012, Pages 260-266

  Tiwari, A K ^a   Zai, C C ^a   Likhodi, O ^a   Voineskos, A N ^a   Meltzer, H Y ^b   Lieberman, J A ^c   Potkin, S G ^d   Remington, G ^a   Muller D J ^a   Kennedy, J L ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b VANDERBILT UNIVERSITY   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

association; CNR1; genetics; movement; schizophrenia; tardive dyskinesia

Indexed keywords

CANNABINOID 1 RECEPTOR;

ADULT; ALLELE; ARTICLE; CNR1 GENE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MOVEMENT DISORDERS; ODDS RATIO; ONTARIO; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, CANNABINOID, CB1; RISK ASSESSMENT; RISK FACTORS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 84861460122     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.93     Document Type: Article

References (47)

1. Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 1991; 4: 109-120.
2. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581-1589. (Pubitemid 36578993)
3. Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008; 193: 279-288.
4. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008; 21: 151-156. (Pubitemid 351339869)
5. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006; 21: 589-598. (Pubitemid 43792739)
6. Gerlach J. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry 2002; 14: 47-57. (Pubitemid 34538832)
7. Marsalek M. Tardive drug-induced extrapyramidal syndromes. Pharmacopsychiatry 2000; 33 (Suppl 1): 14-33.
8. Muller DJ, Schulze TG, Knapp M, Held T, Krauss H, Weber T et al. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand 2001; 104: 375-379. (Pubitemid 34280554)
9. Muller DJ, Shinkai T, De Luca V, Kennedy JL. Clinical implications of pharmacogenomics for tardive dyskinesia. Pharmacogenomics J 2004; 4: 77-87. (Pubitemid 38499990)
10. Thelma B, Srivastava V, Tiwari AK. Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. Pharmacogenomics 2008; 9: 1285-1306.
11. Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 2008; 14: 923-930.
12. Hudson BD, Hebert TE, Kelly ME. Ligand- and heterodimer-directed signaling of the CB(1) cannabinoid receptor. Mol Pharmacol 2010; 77: 1-9.
13. van der Stelt M, Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 2003; 480: 133-150. (Pubitemid 37410366)
14. Matyas F, Yanovsky Y, Mackie K, Kelsch W, Misgeld U, Freund TF. Subcellular localization of type 1 cannabinoid receptors in the rat basal ganglia. Neuroscience 2006; 137: 337-361. (Pubitemid 43031500)
15. Fernandez-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol 2009; 156: 1029-1040.
16. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989; 12: 366-375. (Pubitemid 19238787)
17. Surmeier DJ, Ding J, Day M, Wang Z, Shen W. D1 and D2 dopaminereceptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 2007; 30: 228-235. (Pubitemid 46654239)
18. Kreitzer AC, Malenka RC. Striatal plasticity and basal ganglia circuit function. Neuron 2008; 60: 543-554.
19. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 1999; 96: 5780-5785. (Pubitemid 29234695)
20. Martin AB, Fernandez-Espejo E, Ferrer B, Gorriti MA, Bilbao A, Navarro M et al. Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neuropsychopharmacology 2008; 33: 1667-1679. (Pubitemid 351684717)
21. Rodriguez de Fonseca F, Del Arco I, Martin-Calderon JL, Gorriti MA, Navarro M. Role of the endogenous cannabinoid system in the regulation of motor activity. Neurobiol Dis 1998; 5 (6 Part B): 483-501. (Pubitemid 29075847)
22. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 1999; 2: 358-363. (Pubitemid 30491279)
23. Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 2007; 445: 643-647. (Pubitemid 46232883)
24. Shen W, Flajolet M, Greengard P, Surmeier DJ. Dichotomous dopaminergic control of striatal synaptic plasticity. Science 2008; 321: 848-851.
25. Zai CC, Hwang RW, De Luca V, Muller DJ, King N, Zai GC et al. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol 2007; 10: 639-651. (Pubitemid 47517514)
26. Zai CC, Romano-Silva MA, Hwang R, Zai GC, Deluca V, Muller DJ et al. Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia. Schizophr Res 2008; 106: 248-252.
27. Zai CC, Tiwari AK, De Luca V, Muller DJ, Bulgin N, Hwang R et al. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. Eur Neuropsychopharmacol 2009; 19: 317-328.
28. Zai CC, Tiwari AK, Basile V, de Luca V, Muller DJ, Voineskos AN et al. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and superoxide dismutase 2 (SOD2, MnSOD) genes. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 50-56.
29. Guy W. ECDEU Assessment Manual for Psychopharmacology (revised edn.) Department of Health, Education and Welfare: Washington, DC, 1976.
30. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39: 486-487. (Pubitemid 12152819)
31. Basile VS, Masellis M, Badri F, Paterson AD, Meltzer HY, Lieberman JA et al. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 1999; 21: 17-27. (Pubitemid 29253832)
32. Lieberman J, Kane JM, Woerner M, Weinhold P, Basavaraju N, Kurucz J et al. Prevalence of tardive dyskinesia in elderly samples. Psychopharmacol Bull 1984; 20: 382-386. (Pubitemid 14090995)
33. Lieberman J, Johns C, Cooper T, Pollack S, Kane J. Clozapine pharmacology and tardive dyskinesia. Psychopharmacology (Berl) 1989; 99(Suppl): S54-S59. (Pubitemid 19244140)
34. Lahiri DK, Nurnberger Jr JI. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991; 19: 5444.
35. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003; 25: 115-121. (Pubitemid 37064867)
36. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265. (Pubitemid 40202029)
37. Gauderman WJ, Morrison JM. QUANTO 1.1: a computer program for power and sample size calculations for genetic-epidemiology studies, http://hydra.usc.edu/ gxe, 2006.
38. Tiwari AK, Zai CC, Likhodi O, Lisker A, Singh D, Souza RP, et al. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacology 2010; 35: 1315-1324.
39. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004; 74: 765-769. (Pubitemid 38420107)
40. Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity 2005; 95: 221-227. (Pubitemid 43093236)
41. Zhang PW, Ishiguro H, Ohtsuki T, Hess J, Carillo F, Walther D et al. Human cannabinoid receptor 1: 50 exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry 2004; 9: 916-931. (Pubitemid 39381956)
42. Pabst O, Forster R, Lipp M, Engel H, Arnold HH. NKX2.3 is required for MAdCAM-1 expression and homing of lymphocytes in spleen and mucosa-associated lymphoid tissue. EMBO J 2000; 19: 2015-2023. (Pubitemid 30237577)
43. Fisher SA, Tremelling M, Anderson CA, Gwilliam R, Bumpstead S, Prescott NJ et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet 2008; 40: 710-712. (Pubitemid 351748865)
44. Franke A, Balschun T, Karlsen TH, Hedderich J, May S, Lu T et al. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet 2008; 40: 713-715. (Pubitemid 351748866)
45. Van Limbergen J, Wilson DC, Satsangi J. The genetics of Crohn's disease. Annu Rev Genomics Hum Genet 2009; 10: 89-116.
46. Andersen B, Schonemann MD, Pearse II RV, Jenne K, Sugarman J, Rosenfeld MG. Brn-5 is a divergent POU domain factor highly expressed in layer IV of the neocortex. J Biol Chem 1993; 268: 23390-23398. (Pubitemid 23328062)
47. Hayashida T, Takahashi F, Chiba N, Brachtel E, Takahashi M, Godin-Heymann N et al. HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci USA 2010; 107: 1100-1105.